참고문헌
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. https://doi.org/10.1200/JCO.2007.15.0375
- Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70. https://doi.org/10.1097/JTO.0b013e3181f7c6d4
- Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. https://doi.org/10.1056/NEJMoa061884
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Non-small cell lung cancer version 2.2013 [Internet]. Fort Washington: National Comprehensive Cancer Network; 2013 [cited 2013 Aug 19]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl.
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. https://doi.org/10.1056/NEJMoa0810699
- Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42. https://doi.org/10.1016/S1470-2045(11)70184-X
- Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010;363:1693-703. https://doi.org/10.1056/NEJMoa1006448
- Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85. https://doi.org/10.1097/JTO.0b013e318206a221
- Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013;137:668-84. https://doi.org/10.5858/arpa.2012-0263-RA
- Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-59. https://doi.org/10.1097/JTO.0b013e318290868f
- Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples: practical approach of a working group. Lung Cancer 2012;76:1-18. https://doi.org/10.1016/j.lungcan.2011.10.017
- Moreira AL, Thornton RH. Personalized medicine for nonsmall-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clin Lung Cancer 2012;13:334-9. https://doi.org/10.1016/j.cllc.2012.01.004
- Rivera MP, Mehta AC; American College of Chest Physicians. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3Suppl):131S-48S. https://doi.org/10.1378/chest.07-1357
- Kulesza P, Ramchandran K, Patel JD. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol 2011;136:228-38. https://doi.org/10.1309/AJCPO66OIRULFNLZ
- Alsharif M, Carlo-Demovich J, Massey C, Madory JE, Lewin D, Medina AM, et al. Telecytopathology for immediate evaluation of fine-needle aspiration specimens. Cancer Cytopathol 2010;118:119-26. https://doi.org/10.1002/cncy.20074
- Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, et al. Suitability of endobronchial ultrasoundguided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med 2012;185:1316-22. https://doi.org/10.1164/rccm.201202-0294OC
- Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasoundguided transbronchial needle aspiration. Clin Cancer Res 2010;16:4938-45. https://doi.org/10.1158/1078-0432.CCR-10-0099
- Aisner DL, Marshall CB. Molecular pathology of nonsmall cell lung cancer: a practical guide. Am J Clin Pathol 2012;138:332-46. https://doi.org/10.1309/AJCPFR12WJKCEEZZ
- Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-7. https://doi.org/10.1097/JTO.0b013e3181d40fac
- Mukhopadhyay S, Katzenstein AL. Subclassification of nonsmall cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25. https://doi.org/10.1097/PAS.0b013e3182036d05
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. https://doi.org/10.1056/NEJMoa040938
- Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81. https://doi.org/10.1038/nrc2088
- Kim WS, Choi YD, Seo JW, Han JH, Kim MJ, Kim L, et al. Epidermal growth factor receptor mutation analysis of non-small cell lung cancer in South Korea: summary from a nationwide survey. J Lung Cancer 2010;9 Suppl 2:S38.
- Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013;8:52-61. https://doi.org/10.1097/JTO.0b013e3182769aa8
- Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 2013;66:79-89. https://doi.org/10.1136/jclinpath-2012-201194
- Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4954-5. https://doi.org/10.1158/1078-0432.CCR-07-1387
- Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, et al. A diagnostic algorithm using EGFR mutationspecific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer 2012;78:39-44. https://doi.org/10.1016/j.lungcan.2012.07.002
- Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. https://doi.org/10.1038/nature05945
- Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203. https://doi.org/10.1016/j.cell.2007.11.025
- Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009;4:1450-4. https://doi.org/10.1097/JTO.0b013e3181c4dedb
- Murakami Y, Mitsudomi T, Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol 2012;2:24.
- Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53. https://doi.org/10.1200/JCO.2009.22.6993
- Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013;119:1467-77. https://doi.org/10.1002/cncr.27913
- Marchetti A, Ardizzoni A, Papotti M, Crino L, Rossi G, Gridelli C, et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J Thorac Oncol 2013;8:352-8. https://doi.org/10.1097/JTO.0b013e31827d5280
- Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011;6:466-72. https://doi.org/10.1097/JTO.0b013e31820b82e8
- Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76:403-9. https://doi.org/10.1016/j.lungcan.2011.11.008
피인용 문헌
- Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma vol.29, pp.6, 2014, https://doi.org/10.1097/rti.0000000000000116
- Current and future molecular diagnostics in non-small-cell lung cancer vol.15, pp.8, 2013, https://doi.org/10.1586/14737159.2015.1063420
- New immunohistochemical markers in the differential diagnosisof nonsmall cell lung carcinoma vol.46, pp.6, 2013, https://doi.org/10.3906/sag-1501-68
- A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients vol.15, pp.6, 2013, https://doi.org/10.3892/mmr.2017.6530